One Drop App With an Activity Tracker for Adults With Type 1 Diabetes: Randomized Controlled Trial
BackgroundIn 2017, mobile app support for managing diabetes was available to 64% of the global population of adults with diabetes. One Drop’s digital therapeutics solution includes an evidence-based mobile app with global reach, a Bluetooth-connected glucometer, and in-app coaching from Certified Di...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
JMIR Publications
2020-09-01
|
| Series: | JMIR mHealth and uHealth |
| Online Access: | http://mhealth.jmir.org/2020/9/e16745/ |
| _version_ | 1819280395676418048 |
|---|---|
| author | Osborn, Chandra Y Hirsch, Ashley Sears, Lindsay E Heyman, Mark Raymond, Jennifer Huddleston, Brian Dachis, Jeff |
| author_facet | Osborn, Chandra Y Hirsch, Ashley Sears, Lindsay E Heyman, Mark Raymond, Jennifer Huddleston, Brian Dachis, Jeff |
| author_sort | Osborn, Chandra Y |
| collection | DOAJ |
| description | BackgroundIn 2017, mobile app support for managing diabetes was available to 64% of the global population of adults with diabetes. One Drop’s digital therapeutics solution includes an evidence-based mobile app with global reach, a Bluetooth-connected glucometer, and in-app coaching from Certified Diabetes Educators. Among people with type 1 diabetes and an estimated hemoglobin A1c level≥7.5%, using One Drop for 3 months has been associated with an improved estimated hemoglobin A1c level of 22.2 mg/dL (–0.80%). However, the added value of integrated activity trackers is unknown.
ObjectiveWe conducted a pragmatic, remotely administered randomized controlled trial to evaluate One Drop with a new-to-market activity tracker against One Drop only on the 3-month hemoglobin A1c level of adults with type 1 diabetes.
MethodsSocial media advertisements and online newsletters were used to recruit adults (≥18 years old) diagnosed (≥1 year) with T1D, naïve to One Drop’s full solution and the activity tracker, with a laboratory hemoglobin A1c level≥7%. Participants (N=99) were randomized to receive One Drop and the activity tracker or One Drop only at the start of the study. The One Drop only group received the activity tracker at the end of the study. Multiple imputation, performed separately by group, was used to correct for missing data. Analysis of covariance models, controlling for baseline hemoglobin A1c, were used to evaluate 3-month hemoglobin A1c differences in intent-to-treat (ITT) and per protocol (PP) analyses.
ResultsThe enrolled sample (N=95) had a mean age of 41 (SD 11) years, was 73% female, 88% White, diagnosed for a mean of 20 (SD 11) years, and had a mean hemoglobin A1c level of 8.4% (SD 1.2%); 11% of the participants did not complete follow up. Analysis of covariance assumptions were met for the ITT and PP models. In ITT analysis, participants in the One Drop and activity tracker condition had a significantly lower 3-month hemoglobin A1c level (mean 7.9%, SD 0.60%, 95% CI 7.8-8.2) than that of the participants in the One Drop only condition (mean 8.4%, SD 0.62%, 95% CI 8.2-8.5). In PP analysis, participants in the One Drop and activity tracker condition also had a significantly lower 3-month hemoglobin A1c level (mean 7.9%, SD 0.59%, 95% CI 7.7-8.1) than that of participants in the One Drop only condition (mean 8.2%, SD 0.58%, 95% CI 8.0-8.4).
ConclusionsParticipants exposed to One Drop and the activity tracker for the 3-month study period had a significantly lower 3-month hemoglobin A1c level compared to that of participants exposed to One Drop only during the same timeframe. One Drop and a tracker may work better together than alone in helping people with type 1 diabetes.
Trial RegistrationClinicalTrials.gov NCT03459573; https://clinicaltrials.gov/ct2/show/NCT03459573. |
| first_indexed | 2024-12-24T00:43:07Z |
| format | Article |
| id | doaj.art-59a91b5fe90844afb97f19aa8a357ce0 |
| institution | Directory Open Access Journal |
| issn | 2291-5222 |
| language | English |
| last_indexed | 2024-12-24T00:43:07Z |
| publishDate | 2020-09-01 |
| publisher | JMIR Publications |
| record_format | Article |
| series | JMIR mHealth and uHealth |
| spelling | doaj.art-59a91b5fe90844afb97f19aa8a357ce02022-12-21T17:23:53ZengJMIR PublicationsJMIR mHealth and uHealth2291-52222020-09-0189e1674510.2196/16745One Drop App With an Activity Tracker for Adults With Type 1 Diabetes: Randomized Controlled TrialOsborn, Chandra YHirsch, AshleySears, Lindsay EHeyman, MarkRaymond, JenniferHuddleston, BrianDachis, JeffBackgroundIn 2017, mobile app support for managing diabetes was available to 64% of the global population of adults with diabetes. One Drop’s digital therapeutics solution includes an evidence-based mobile app with global reach, a Bluetooth-connected glucometer, and in-app coaching from Certified Diabetes Educators. Among people with type 1 diabetes and an estimated hemoglobin A1c level≥7.5%, using One Drop for 3 months has been associated with an improved estimated hemoglobin A1c level of 22.2 mg/dL (–0.80%). However, the added value of integrated activity trackers is unknown. ObjectiveWe conducted a pragmatic, remotely administered randomized controlled trial to evaluate One Drop with a new-to-market activity tracker against One Drop only on the 3-month hemoglobin A1c level of adults with type 1 diabetes. MethodsSocial media advertisements and online newsletters were used to recruit adults (≥18 years old) diagnosed (≥1 year) with T1D, naïve to One Drop’s full solution and the activity tracker, with a laboratory hemoglobin A1c level≥7%. Participants (N=99) were randomized to receive One Drop and the activity tracker or One Drop only at the start of the study. The One Drop only group received the activity tracker at the end of the study. Multiple imputation, performed separately by group, was used to correct for missing data. Analysis of covariance models, controlling for baseline hemoglobin A1c, were used to evaluate 3-month hemoglobin A1c differences in intent-to-treat (ITT) and per protocol (PP) analyses. ResultsThe enrolled sample (N=95) had a mean age of 41 (SD 11) years, was 73% female, 88% White, diagnosed for a mean of 20 (SD 11) years, and had a mean hemoglobin A1c level of 8.4% (SD 1.2%); 11% of the participants did not complete follow up. Analysis of covariance assumptions were met for the ITT and PP models. In ITT analysis, participants in the One Drop and activity tracker condition had a significantly lower 3-month hemoglobin A1c level (mean 7.9%, SD 0.60%, 95% CI 7.8-8.2) than that of the participants in the One Drop only condition (mean 8.4%, SD 0.62%, 95% CI 8.2-8.5). In PP analysis, participants in the One Drop and activity tracker condition also had a significantly lower 3-month hemoglobin A1c level (mean 7.9%, SD 0.59%, 95% CI 7.7-8.1) than that of participants in the One Drop only condition (mean 8.2%, SD 0.58%, 95% CI 8.0-8.4). ConclusionsParticipants exposed to One Drop and the activity tracker for the 3-month study period had a significantly lower 3-month hemoglobin A1c level compared to that of participants exposed to One Drop only during the same timeframe. One Drop and a tracker may work better together than alone in helping people with type 1 diabetes. Trial RegistrationClinicalTrials.gov NCT03459573; https://clinicaltrials.gov/ct2/show/NCT03459573.http://mhealth.jmir.org/2020/9/e16745/ |
| spellingShingle | Osborn, Chandra Y Hirsch, Ashley Sears, Lindsay E Heyman, Mark Raymond, Jennifer Huddleston, Brian Dachis, Jeff One Drop App With an Activity Tracker for Adults With Type 1 Diabetes: Randomized Controlled Trial JMIR mHealth and uHealth |
| title | One Drop App With an Activity Tracker for Adults With Type 1 Diabetes: Randomized Controlled Trial |
| title_full | One Drop App With an Activity Tracker for Adults With Type 1 Diabetes: Randomized Controlled Trial |
| title_fullStr | One Drop App With an Activity Tracker for Adults With Type 1 Diabetes: Randomized Controlled Trial |
| title_full_unstemmed | One Drop App With an Activity Tracker for Adults With Type 1 Diabetes: Randomized Controlled Trial |
| title_short | One Drop App With an Activity Tracker for Adults With Type 1 Diabetes: Randomized Controlled Trial |
| title_sort | one drop app with an activity tracker for adults with type 1 diabetes randomized controlled trial |
| url | http://mhealth.jmir.org/2020/9/e16745/ |
| work_keys_str_mv | AT osbornchandray onedropappwithanactivitytrackerforadultswithtype1diabetesrandomizedcontrolledtrial AT hirschashley onedropappwithanactivitytrackerforadultswithtype1diabetesrandomizedcontrolledtrial AT searslindsaye onedropappwithanactivitytrackerforadultswithtype1diabetesrandomizedcontrolledtrial AT heymanmark onedropappwithanactivitytrackerforadultswithtype1diabetesrandomizedcontrolledtrial AT raymondjennifer onedropappwithanactivitytrackerforadultswithtype1diabetesrandomizedcontrolledtrial AT huddlestonbrian onedropappwithanactivitytrackerforadultswithtype1diabetesrandomizedcontrolledtrial AT dachisjeff onedropappwithanactivitytrackerforadultswithtype1diabetesrandomizedcontrolledtrial |